Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 18Trastuzumab 7Docetaxel 7Paclitaxel 6Magnetic Resonance Spectroscopy 5Taxes 4Drug Therapy 4Carboplatin 4Specimen Handling 3Psychiatric Rehabilitation 3Polymerase Chain Reaction 3Nivolumab 3Injections 3Fluorouracil 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Cisplatin 3Capecitabine 3Biopsy 3poly ICLC 2fludarabine 2durvalumab 2belinostat 2atezolizumab 2Radiotherapy 2Oxaliplatin 2Leucovorin 2Lapatinib 2Irinotecan 2Interleukin-12 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Dihydrouracil Dehydrogenase (NADP) × Breast × Clear all
NCT05266300 2022-11-01

Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.

University of Southern Denmark

Completed
722 enrolled
BreastGastrointestinal

Bile Duct Neoplasms, Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡